Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
25.70
-0.60 (-2.28%)
Sep 26, 2024, 4:00 PM EDT - Market closed
Company Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors.
Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Claire Mazumdar Clemon |
Contact Details
Address: 116 Huntington Avenue, Suite 703 Boston, Massachusetts 02116 United States | |
| Phone | 617-468-4219 |
| Website | bicara.com |
Stock Details
| Ticker Symbol | BCAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0002023658 |
| ISIN Number | US0554771032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Claire Mazumdar, Ph.D., M.B.A. | Chief Executive Officer and Director |
| Ryan Cohlhepp, Pharm.D. | President, Chief Operating Officer |
| Ivan Hyep, M.B.A. | Chief Financial Officer |
| David Raben, M.D. | Chief Medical Officer |
| Lara Meisner, J.D. | Chief Legal Officer |
| Nils Lonberg, Ph.D. | Director |
| Carolyn Ng, Ph.D. | Director |
| Vijay Kuchroo, D.V.M., Ph.D. | Director |
| Kiran Mazumdar-Shaw | Director |
| Heath Lukatch, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 18, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 16, 2024 | 8-K | Current Report |
| Sep 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 13, 2024 | 424B4 | Prospectus |
| Sep 12, 2024 | EFFECT | Notice of Effectiveness |
| Sep 12, 2024 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Sep 12, 2024 | CERT | Certification by an exchange approving securities for listing |